Crow Point Partners’s iShares Biotechnology ETF IBB Stock Holding History

Crow Point Partners’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,900	Closed	-$207K	–	133
2019 Q2	$207K	Buy	+1,900	New	+$202K	0.03%	105
2017 Q4	–	Sell	-3,180	Closed	-$350K	–	269
2017 Q3	$350K	Buy	+3,180	New	+$340K	0.06%	121

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Crow Point Partners's IBB Position: Q3 2019 in Review

Crow Point Partners sold out of iShares Biotechnology ETF (IBB) in Q3 2019, closing a stake of 1,900 shares — an estimated $207K sold.

Crow Point Partners first reported a position in IBB in Q3 2017 and held it in 2 quarters. The position peaked at $350K in Q3 2017. 597 funds tracked by Wall St. Rank hold IBB as of Q3 2019.

Crow Point Partners reported no remaining iShares Biotechnology ETF position as of Q3 2019 after selling out during the quarter.
Crow Point Partners sold 1,900 iShares Biotechnology ETF shares in Q3 2019, an estimated $207K.
Crow Point Partners first reported a position in iShares Biotechnology ETF in Q3 2017 and held it in 2 quarters.
Crow Point Partners's iShares Biotechnology ETF position peaked at $350K in Q3 2017.
597 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2019.

Based on Crow Point Partners's 13F filing for Q3 2019, filed 9 Oct 2019.